Financial
FY2026 revenue $5.65bn (+9.9%); operating margin 33.4%; net income $1.52bn.
Cash $1.47bn; debt $659.4m.
ResMed
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: RMD
FY2026 revenue $5.65bn (+9.9%); operating margin 33.4%; net income $1.52bn.
Cash $1.47bn; debt $659.4m.
Source: official results release · Year ended 2026-06-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | US$5.7bn | +9.9% | US$1.9bn | US$1.5bn | ResMed |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.